The contemporary role of renal mass biopsy in the management of small renal tumors by Amy Lim et al.
REVIEW ARTICLE
published: 10 September 2012
doi: 10.3389/fonc.2012.00106
The contemporary role of renal mass biopsy in the
management of small renal tumors
Amy Lim1, Brock O’Neil 2, Marta E. Heilbrun3, Christopher Dechet2 and William T. Lowrance2*
1 MD/PhD Program, University of Utah, Salt Lake City, UT, USA
2 Division of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
3 Department of Radiology, University of Utah, Salt Lake City, UT, USA
Edited by:
Paul Russo, Memorial Sloan
Kettering Cancer Center, USA
Reviewed by:
Agnieszka Michael, University of
Surrey, UK
Adam R. Metwalli, National
Institutes of Health, USA
*Correspondence:
William T. Lowrance, Division of
Urology, Department of Surgery,
Huntsman Cancer Institute,
University of Utah, 1950 Circle of
Hope, Suite 6405, Salt Lake City,
UT 84112, USA.
e-mail: will.lowrance@hci.utah.edu
The selective use of percutaneous biopsy for diagnosis in renal masses is a relatively
uncommon approach when compared to the management of other solid neoplasms. With
recent advancements in imaging techniques and their widespread use, the incidental
discovery of asymptomatic, small renal masses (SRM) is on the rise and a substantial
percentage of these SRM are benign. Recent advances in diagnostics have significantly
improved accuracy rates of renal mass biopsy (RMB), making it a potentially powerful tool
in the management of SRM. In this review, we will discuss the current management
of SRM, problems with the traditional view of RMB, improvements in the diagnostic
power of RMB, cost-effectiveness of RMB, and risks associated with RMB. RMB may
offer important information enabling treating clinicians to better risk-stratify patients and
ultimately provide a more personalized treatment approach for SRM.
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INTRODUCTION
In 1971, a review of 309 cases reported that 60% of patients
with renal cell carcinoma presented with hematuria, 30% with
flank pain, and 25% with an abdominal mass. The classic triad
of all three was seen in 9% of patients while only 7% were
asymptomatic (Skinner et al., 1971). Technological advances have
resulted in new methods for detecting and treating renal masses.
Nowmost are discovered incidentally on CT scan (Figure 1) with
only 24% of patients with hematuria, 10% with flank pain, and
8%with an abdominalmass (Jayson and Sanders, 1998). The clas-
sic triad is now rarely seen (0.7%) and 61% are asymptomatic at
detection (Jayson and Sanders, 1998). At the same time the inci-
dence of primary renal malignancies has been steadily increasing
in the United States over the past two decades (Chow et al., 1999),
and the average size of renal masses discovered at presentation is
getting smaller (Nguyen et al., 2006).
Small renal masses (SRM) are defined by a greatest diame-
ter of 4 cm or less and constitute 48–66% of all newly diagnosed
renal tumors and 38% of all excised renal masses (Lee et al., 2000;
Nguyen et al., 2006). The rising trend in the diagnosis of primary
renal malignancies and the detection of renal masses at smaller
sizes is due in part to increasing utilization of sophisticated
diagnostic imaging modalities.
While the logical result of this trend toward an apparent
early detection of more renal masses at a smaller size would
be improved cancer specific survival rates for primary renal
malignancies, this has not been realized with slightly increasing
renal cell carcinoma mortality rates (Hollingsworth et al., 2006).
This suggests that our current treatment paradigm towards renal
tumors or renal masses may not be the most effective for prevent-
ing death from kidney cancer. Additionally, pathologic staging
shows that approximately 20–50% of SRM are benign, and a
subgroup of the malignantmasses are likely indolent (Frank et al.,
2003; Nguyen et al., 2006; Russo, 2008). Therefore, the benefits of
aggressive surgical management for some SRM may not always
outweigh the associated risks.
One long discussed, but infrequently utilized approach to
help selectively apply the benefits of surgical management
without over treatment is the renal mass biopsy (RMB). In
this review, we will discuss the current management of SRM,
problems with the traditional view of RMB, improvements in
the diagnostic power of RMB, cost-effectiveness of RMB, and
risks associated with RMB, arguing that RMB offers important
information for treating clinicians to risk-stratify patients with
SRM.
TREATMENT OPTIONS FOR SRM
SURGICAL MANAGEMENT: RADICAL AND PARTIAL NEPHRECTOMY
Localized solid SRM are typically treated with either nephron-
sparing surgery (NSS) or radical nephrectomy. Other man-
agement options include active surveillance (AS) or ablative
(radiofrequency or cryoablation) therapies. For renal lesions that
are amenable to NSS, partial nephrectomy is typically favored
over radical nephrectomy for several reasons. First, rates of
chronic kidney disease (CKD) are rising and partial nephrectomy
clearly preserves renal function compared to radical nephrectomy
(Coresh et al., 2007). This benefit was demonstrated by Huang
et al. who retrospectively analyzed 662 patients with normal base-
line renal function and subsequently underwent partial or radical
nephrectomy for SRM. Only 3% of these patients who underwent
partial nephrectomy developed new onset of CKD compared to
36% of patients who underwent radical nephrectomy. Second,
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FIGURE 1 | (A) A single axial CT image from a percutaneous CT guided
biopsy using a coaxial technique and a 22-guage needle for fine needle
aspirate sampling in a female with an incidentally detected 2.7 cm lower
pole R renal mass. Pathology reported renal cell carcinoma, without
subtyping. (B) An ultrasound image with the needle guide in place of a
male with an incidentally detected 3.5 cm right upper pole renal mass.
(C) A second ultrasound image from a percutaneous US guided biopsy using
a coaxial technique and an 18-guage needle for core biopsy. Pathology
reported as renal cell carcinoma, conventional clear cell type, Furman
grade I–II.
NSS results in similar oncological control when compared to
radical nephrectomy (Becker et al., 2006; Thompson et al., 2008).
Third, radical nephrectomy and partial nephrectomy have simi-
lar complication rates (Stephenson et al., 2004; Lowrance et al.,
2010).
Although partial nephrectomy is the preferred surgical treat-
ment for SRM, according to Surveillance, Epidemiology and
End Results data, only 35% of SRM are removed by this
method while the remaining 65% continue to undergo rad-
ical nephrectomy (Dulabon et al., 2010). Underutilization of
partial nephrectomy is likely multifactorial, but may be partly
due to the comfort level of surgeons performing this tech-
nically demanding procedure or to patient access to ter-
tiary care centers providing this service. Underutilization of
nephron-sparing treatments is concerning, given that approx-
imately 20–50% of renal masses are benign, placing a size-
able group of patients at risk for CKD for a procedure that
may be unnecessary (Russo et al., 2012). RMB may help
elucidate which patients are likely to benefit from extirpa-
tive therapy and reassure clinicians monitoring patients who
are not.
NON-SURGICAL OPTIONS: ACTIVE SURVEILLANCE AND ABLATION
AS and image-guided tumor ablation are non-traditional
treatment options for SRM. Typically, these modalities are
reserved for patients with complicated coexisting morbidities,
limited life expectancy, have other significant surgical risk fac-
tors, or due to patient preference. However, AS may be suited
for additional groups if clinicians were better able to risk stratify
patients.
AS is especially appealing for smaller masses as it has been
shown that small size (Frank et al., 2003) and slow growth
rates (Kouba et al., 2007; Abouassaly et al., 2008; Boorjian
and Uzzo, 2009; Jewett et al., 2011; Smaldone et al., 2012)
correlate with a low malignancy potential. Further, evidence
suggests that malignancy rates for patients managed by AS are
not statistically different from select patients managed through
partial nephrectomy or ablative therapies (Abou Youssif et al.,
2007; Kunkle et al., 2007), and delayed surgical intervention as
a result of AS does not appear to compromise surgical outcomes
(Kouba et al., 2007; Boorjian and Uzzo, 2009). Collectively, these
data suggest that AS is an option for SRM in select patients,
although randomized studies comparing AS to early intervention
for SRM with long-term follow-up are needed to fully endorse
this approach.
Image-guided tumor ablation is an additional treatment
option with favorable short-term outcomes. However, long-term
robust oncological data is not yet available. Berger et al. (2009)
reported reasonable 5 and 10-year radiographic cancer-specific
survival rates at 93 and 81%, respectively. Yet these rates are less
successful compared to partial nephrectomy, where five and 10-
year cancer-specific survival rates are as high as 96 and 90%,
respectively (Chawla et al., 2006).
Radiofrequency ablation is also utilized for primary
management of SRM but is reported to have higher recurrence
rates when compared to cryoablation. This difference does not
appear to affect metastatic progression (Kunkle and Uzzo, 2008;
Heuer et al., 2010). One must also consider that prior ablative
therapy may complicate salvage therapy by partial nephrectomy
due to significant fibrosis (Crowley et al., 2001; Zhu et al., 2006;
Nguyen and Campbell, 2008; Kowalczyk et al., 2009). Although
surgical excision has better long-term oncologic outcomes,
RMB may be helpful in guiding treatment decisions for patients
considering other options.
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PROBLEMS WITH THE TRADITIONAL VIEW OF RENAL
MASS BIOPSY
RMB is currently uncommonly used in the evaluation of newly
discovered SRM. In one population-based medical claims anal-
ysis, only 6% of patients undergoing nephrectomy (partial or
radical) for a renal tumor had a preoperative renal biopsy per-
formed within the 6 months prior to surgery (Lowrance et al.,
2011). Conventional thinking about the value of percutaneous
renal biopsy has deterred most physicians from utilizing this as
a diagnostic tool in the decision of how to manage SRM. This
is at least partly due to reported false positive rates of up to
5%, but more significantly, false negative rates as high as 25%.
Physicians may also be hesitant to biopsy if their institution lacks
Interventional Radiologists that routinely perform this proce-
dure, which would inherently affect the rate of failed biopsies.
With reported failure rates of 0–22% prior to 2001 and 0–18%
from 2001 onward (Lane et al., 2008), it is reasonable that physi-
cians would take a more conservative approach in utilizing biopsy
as a diagnostic procedure. Finally, there is a strong belief that RMB
will not change management (Khan et al., 2007).
High false negative rates are slightly misleading and outdated
as underscored by a meta-analysis of 2474 renal mass biopsies
by Lane et al. First, the false-negative rates were originally cal-
culated from both failed biopsies and misinterpreted results as
opposed to only negative results. When these biopsies were rean-
alyzed and more appropriately categorized as technical failures
instead of negative test results, the false-negative rates and positive
rates were 4.4 and 1.2%, respectively. Second, if the first biopsy
is not helpful, repeat biopsy can be utilized to decrease the rate
of biopsy failures for indeterminate or failed biopsies (Murphy
et al., 1985; Nadel et al., 1986; Wood et al., 1999; Shannon et al.,
2008). Third, false positive and negative rates are improving with
advancements in imaging, biopsy technique, immunohistochem-
istry and new molecular markers (see section “Advancements in
RMB” below).
With improved false-negatives rates and current reported sen-
sitivities of 80–92% and specificities of 83–100% (Rybicki et al.,
2003; Volpe et al., 2007; Shannon et al., 2008), it is hard to believe
that RMB would not change management. Nonetheless, historic
studies report a wide range of change in management (6.3–
47.8%) based upon response to core biopsy results. Moreover,
inconsistent definitions of “change in management” are so var-
ied that it is often difficult to make meaningful conclusions
from studies that evaluate this criteria (Rybikowski et al., 2008;
Shannon et al., 2008; Thuillier et al., 2008). Yet, others have
reported that RMB provided important information in deter-
mining which patients would be best for AS, NSS, or radical
nephrectomy based upon indeterminate, benign, intermediate, or
unfavorable histology (Tan et al., 2012). Unfortunately they do
not report the favored management choice prior to RMB, limit-
ing conclusions from this type of work, but there appears to be a
relationship between RMB and resultant management.
One of the most significant criticisms of using RMB for man-
agement of SRM is concern regarding accuracy of the biopsy
result. Some use the unreliable surrogate of growth rates to
substitute for surgical pathology in confirming biopsy results.
This has led to reluctance in adopting RMB as a standard.
Dechet et al. (1999) conducted one of the first and largest stud-
ies to have surgical pathology confirmation of RMB. In this study,
renal masses were biopsied twice with an 18-guage needle after
surgical removal. These samples were processed with hematoxylin
and eosin stains, compared to final pathology on the surgical
specimen, and evaluated blindly by two independent uropathol-
ogists. Accuracy for the pathologists was 76% and 80%, with
non-diagnostic rates of 11% and 17%, sensitivity of 77% and
84% specificity 60% and 73%, positive predictive value 94% and
96%, and negative predictive value 69% and 73%. In this ideal
setting in which biopsies were performed ex vivo and then com-
pared to the gold standard of surgical pathology, accuracy rates
were lower than previously reported. This suggests that studies
in which biopsy results are not confirmed by surgical pathology
might lead to an overestimation of the accuracy of RMB.
In a more recent prospective study, Schmidbauer et al. com-
pared pre-operative percutaneous fine-needle and core biopsy
with surgical pathology in 78 patients and report more promis-
ing diagnostic ability (Schmidbauer et al., 2008). They reported
sensitivity for the detection of renal cell carcinoma of greater than
90%, specificity of 100%, positive predictive value of 100%, and a
negative predictive value of 70%. They were also able to correctly
identify Fuhrman grade in 76%, and correct subtype identifica-
tion in 91%. In contrast, a review of 405 preoperative biopsies
from 378 patients from the MD Anderson Cancer Center from
1991 to 2007 showed concordant Fuhrman grades in preoperative
biopsies and nephrectomy specimens in only 38.3% of patients
(Abel et al., 2012). These data demonstrate the wide variability
in accuracy rates of Fuhrman grade from RMB and suggest that
determination of grade may not as useful in managing SRM until
accuracy rates uniformly improve.
Improvements in accuracy rates in multiple studies are diffi-
cult to evaluate due to methodological differences in studies, but
appear to be improving (Chawla et al., 2006; Kunkle et al., 2007).
In the large meta-analysis by Lane et al. accuracy rates prior to
2001 were reported as 88.9% and 96% after 2001. They attribute
this improvement to advances in molecular diagnostics.
ADVANCEMENTS IN RENAL MASS BIOPSY
Some of the most significant limitations in relying on biopsy are
the heterogeneous nature of SRM and the difficulty distinguish-
ing masses based on histology alone. Recent identification of new
histologic and molecular markers will undoubtedly change the
sensitivity and specificity of subtyping these lesions and aid in
deciding which lesions are safe to actively monitor and which
need aggressive early management. Further, characterizing lesions
based on molecular markers, chromosomal changes and gene
expression profiling using PCR, fluorescent in situ hybridiza-
tion (FISH), and microarray analysis will provide information
which may help predict malignancy potential as well as sensi-
tivity to immunotherapy and possibly chemotherapy (Table 1)
(Martignoni et al., 2001; Young et al., 2001; Higgins et al., 2003;
Takahashi et al., 2001; Yao et al., 2005; Zhou et al., 2005; Leppert
et al., 2007; Varona et al., 2010; Koul et al., 2011; Lee et al., 2011;
Samplaski et al., 2011). Molecular subtyping has already been
shown to accurately predict malignancy potential and tumor sen-
sitivities to direct chemotherapy regimens in colorectal and breast
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Table 1 | Molecular markers and genetic alterations of subtypes of renal cell carcinoma.
Renal cell carcinoma subtype Molecular markers Genetic alterations (Koul et al., 2011)
Clear cell (+): GST-α, Vimentin, ADFP, CA-IX, EMA, LMWCK,
CD10, Caveolin-1, MOC-31, CD26
−3p25, +5q22, −6q, −8p12, −9p21, −9q22,
−10q, −14q
(−): K19, AMACR, Keratin 7, CK20, CK7, HMWCK, Ron,
Parvalbumin
Papillary (+): AMACR, CA-II Keratin 7, CD 10, CD15, LMWCK +3q, +8, −9p21, +12, −14q, +16, +17q21,+20
(−): GST-α, CA-IX, Ron, Parvalbumin
Chromophobe (+): CA-II, Parvalbumin, CD74, Galactin-3, Cytokeratin
7, Caveolin-1, MOC-31, CK7, E-cadherin, CD10
−5q22, −8p, −9p23, −18q22
(−): AMACR, K19, Vimentin, ADFP, HMWCK, Ron,
CD26
Oncocytoma (+): CA-II, Parvalbumin, Ron, Galectin-3, CD 10,
LMWCK, E-cadherin, Caveolin-1, CD26
−1p, −8p, −11q13, 14q, −19q, −21q, −X/Y,
(−): GST-α, AMACR, K19, Vimentin, CD 74, HMWCK der(13)t(13;16)(p11;p11)
cancer, changing the way patients are managed. Similarly, serum
carbonic anhydrase IX level, and expression levels of CD147,
HIF1-alpha and VEGF have been associated with increased renal
tumor progression and recurrence rates and may be helpful as
predictors of poorer outcomes (Lam et al., 2005; Klatte et al.,
2007; Sandlund et al., 2007; Li et al., 2008; Liang et al., 2009).
One of the most difficult areas in the management of SRM
is being able to histologically distinguish between benign onco-
cytomas and variants of chromophobe renal cell carcinoma on
RMB. Oncocytomas are usually considered benign lesions while
chromophobe tumors have a more malignant potential (Amin
et al., 1997; Perez-Ordonez et al., 1997; Cheville et al., 2003).
Although these two types of tumors are difficult to distinguish
by cellular morphology, they can be distinguished using multi-
ple defining histologic andmolecular characteristics (Young et al.,
2001; Kuroda et al., 2004; Adley et al., 2006; Garcia and Li, 2006;
Huang et al., 2009; Samplaski et al., 2011), with published accu-
racy rates as high as 94% for distinguishing between renal cell
carcinoma and oncocytomawhen combining histology with FISH
(Barocas et al., 2007).
Additional markers such as Caveolin-1, which was shown to
be positive in 87% of chromophobe RCCs (20 of 23) and 0%
of oncocytomas (0 of 8) and MOC-31, which was positive in
96% (22 of 23) of chromophobe RCCs and only 25% (2 of
8) of oncocytomas may also provide clinically important data
(Lee et al., 2011). Moreover, different permutations of Cyclin
D1 expression levels and rearrangement of the CCND1 locus
can help differentiate oncocytomas and chromophobe renal cell
(Sukov et al., 2009). Further advancements in determining unique
cellular and molecular characteristics will help identify tumor
subtypes, although the number of assays run on a single sam-
ple may be limited by the amount of tissue available from core
biopsies.
Finally, it should be noted that improved accuracy rates are
not only due to more molecular markers, but also likely due to
experienced uropathologists familiar with the renal cell tumor
histology. The interpretation of the biopsy results will be very
dependent on the expertise of the pathologists. The role of renal
biopsy is not proven amongst a general population of pathologists
and therefore the interpretation should be limited at this point to
pathologists with this expertise.
PREDICTING TUMOR BEHAVIOR
Currently, RMB is generally indicated for those with known
extrarenal malignancy, suspected lymphoma, prior to and after
ablation of a renal mass and to rule out an infectious etiology of
a renal mass (Sahni and Silverman, 2009). Histological subtype
and to a more varying degree, Fuhrman Grade can be determined
by biopsy in most cases (Lechevallier et al., 2000; Neuzillet et al.,
2004; Lebret et al., 2007; Shannon et al., 2008; Blumenfeld et al.,
2010). However, even within these subtypes and grades, signif-
icant variation can occur in terms of aggressiveness, recurrence
and susceptibility to certain treatments. Researchers are now
looking towards genetic and protein profiling to not only help
more accurately identify subtypes of tumors, but also aid in
predicting outcomes, potential response to targeted systemic
therapy, metastatic behavior and susceptibilities (Oda et al.,
1995; Wu et al., 1996; Young et al., 2001). Barocas et al. (2006)
reported results from 60 core biopsies taken after nephrectomy
and found that histology alone had an accuracy rate of 83.3%,
but in combination by PCR based gene expression techniques the
accuracy rate improved to 95%.
Takahashi et al. (2001) identified expression of 40 genes asso-
ciated with worse outcomes in clear cell renal carcinoma. Using
this molecular profile, they were able to more accurately predict
the course of disease (96% of cases) when compared to staging
alone. In a recent study looking at cytogenetic profiles of patients
with clear cell renal carcinoma, Klatte et al. identified that loss of
certain chromosomes were tightly associated with better or worse
outcomes.
Future work will continue to improve our understanding of
which malignant tumors are likely to behave poorly, further aid-
ing our ability to risk stratify patients with SRM. The Cancer
Genome Atlas (TCGA) is an open resource that provides data
on gene and miRNA expression, DNA methylation and copy
number in several tumor types, including clear cell and pap-
illary cell carcinoma. As the TCGA grows, it will become a
valuable resource in understanding many aspects of renal cell
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carcinoma including pathways affected in these tumors, which
will ultimately drive drug discoveries specifically targeting these
pathways. This is especially important in renal cell carcinomas,
as these tumors are notoriously poor responders to traditional
chemotherapy. This database will certainly serve the community
in a collaborative effort to further expand our understanding
of how molecular biology can serve as a platform for provid-
ing better, patient-specific care. As the dream of personalized
medicine becomes more of a reality, it is easy to envision how
renal biopsy in larger, locally advanced lesions or those associated
with metastatic disease will become integral in the management
of the advanced forms of the disease (Abel et al., 2012). Targeted
therapies are (and more will become) available for specific renal
cell carcinoma subtypes and may prove to be more effective
in the neoadjuvant setting rather than the adjuvant or salvage
setting.
COST-EFFECTIVENESS OF RENAL MASS BIOPSY
An important consideration in the discussion of RMB for SRM
is the economic impact of various treatment approaches. After
considering biopsy performance, the probability of tract seeding,
possibility of growth of the SRM, treatment costs, patient out-
comes, and quality of life, Pandharipande et al. (2010) compared
RMB to surgery or imaging surveillance. Their Markov model
clearly favored RMB in terms of cost-effectiveness.
In a separate analysis using similar methods, Heilbrun et al.
estimated that for a hypothetical healthy 60 year-old man with a
SRM<2 cm, RMB was more cost-effective than immediate treat-
ment for quality adjusted-life years gained (Heilbrun et al., 2012).
Both of these studies argue for additional consideration of RMB
when faced with a SRM.
DIAGNOSTIC VALUE OF IMAGING IN RENAL MASSES
The alternative to utilizing a pre-treatment RMB is to depend
solely on imaging information. Although most enhancing renal
masses are malignant, there are no definitive characteristics of
a renal mass on CT or MRI that can conclusively distinguish
between malignant tumors from benign growths (Choudhary
et al., 2009; Rosenkrantz et al., 2010). Moreover, RMB provides
superior diagnostic accuracy when compared head-to-head with
imaging. Dechet et al. conducted a study where two radiologists
reviewed CT scans from 100 patients with a solid renal mass
and these results were compared to those of pathologists review-
ing core samples. Final diagnoses were determined by surgical
pathology. Utilizing CT imaging alone, the accuracy rates for each
radiologist were 60 and 66%, non-diagnostic rates were 31 and
23%, sensitivities were 70 and 77% and specificities were 20 and
20%, respectively. Pathologists reviewing core biopsy rates were
superior in all categories with accuracy rates of 77 and 72%,
non-diagnostic rates of 20–21%, sensitivities of 81 and 83% and
specificities of 60 and 33% (Dechet et al., 2003). With improve-
ments in RMB as outlined above, diagnostic accuracy may favor
pathologist review even further.
Other work has evaluated the accuracy of imaging for the diag-
nosis of SRM with mixed results. A meta-analysis consisting of
2770 patients undergoing either partial or radical nephrectomy
for SRM demonstrated a relationship between renal mass size
and malignancy. As renal mass size increased, the probability of
being malignant also increased with a 17% increase in the odds of
malignancy with each 1 cm in size (Frank et al., 2003). In contrast,
a retrospective review of 543 patients who underwent surgical
excision compared pre-operative imaging to final pathology. They
found a negative malignancy rate of 14.7% and mass size did
not predict final pathology with 83% of benign masses consid-
ered suspicious for malignancy based upon imaging (Remzi et al.,
2007).
When examining fine needle and core biopsies of patients pre-
senting for percutaneous ablation, Heilbrun et al. (2007) found
imaging to have a positive predictive value of 95% for malignancy
but a non-diagnostic rate of 11.8%. However, a similar study
reported benign core biopsy pathology in 37% of patients with
suspected malignant SRM referred for percutaneous ablation but
their benign results may be falsely inflated as non-diagnostic
biopsies that then later showed no growth on repeat imaging
were categorized as benign (Tuncali et al., 2004). Unfortunately
or primary neither study has surgical pathology for comparison
to confirm the malignant diagnosis.
Considering the limitations of imaging alone to conclusively
determine malignancy, it is hard to argue that RMB would not
offer additional information helpful in improving diagnostic
accuracy and aid in the decision process of who might benefit
more from surgery.
COMPLICATIONS OF RENAL MASS BIOPSY
RMB is not without risks and these should be considered when
deciding whether to pursue this diagnostic procedure. However,
the risks of RMB are low; the most common complications
of RMB include bleeding, arteriovenous fistula formation and
tumor seeding. Reported rates of minor complications from renal
biopsy are less than 5%, major complications are less than 1%
(Lane et al., 2008), and mortality rates are less than 0.1% (Kark
et al., 1958; Slotkin and Madsen, 1962; Muth, 1965).
The most common complication encountered is bleeding,
which is usually subclinical and detected on CT scan during fol-
low up with self-limiting treatment. In one series, bleeding rates
of 91% were reported, however, major bleeding that required
transfusion or hospital observation occurred in only 1.5% of cases
(Tang et al., 2002). Although it is believed that larger-needle biop-
sies (18 gauge or less) are associated with higher risk of bleeding
complications than with smaller-needle biopsies (20 gauge or
more), published studies refute this idea showing that there is no
significant difference in bleeding complications based on needle
size (Gazelle et al., 1992; Wood et al., 1999). Retrospective non-
randomized studies showing a difference in complication rates
with relation to needle size are thought to be a result of biopsy
technique rather than needle size (Manno et al., 2004). It should
be noted when comparing needle gauge size and diagnostic yield,
there was no difference between 18 and 20 needle gauge size
(Beland et al., 2007).
Arteriovenous fistula formation is a complication observed in
1.5–16% of cases (Dorffner et al., 1998). However, a majority of
these are self-limited and clinically insignificant. Approximately
80% of arteriovenous fistulas will resolve on their own in a period
of 3.5–20 months without any intervention (Matsell et al., 1992;
Parrish, 1992; Tzortzis et al., 1998). The remaining may have clin-
ical symptoms such as hematuria, hypertension or alteration in
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kidney function and are usuallymanaged with angioembolization
(Kopecna et al., 2005).
Tumor seeding is a serious concern for any biopsy procedure.
The risk associated with tumor seeding along the needle track in
RMB is rare, with reports of less than 0.01% (Smith, 1991; Volpe
et al., 2007). Transitional cell carcinomas may have a higher risk
for seeding, but this risk is still thought to be low (Wehle and
Grabstald, 1986; Shenoy et al., 1991; Keeley et al., 1997; Herts,
2000). There are additional reports using modern biopsy tech-
niques that have no cases of tumor seeding even in the cases where
transitional cell carcinoma was biopsied (Lechevallier et al., 2000;
Caoili et al., 2002; Neuzillet et al., 2004; Vasudevan et al., 2006).
Another often discussed potential unintended consequence of
RMB is that if surgical management is required, it may make
doing so more complicated. However, increasing evidence sug-
gests that previous biopsy does not result in increased surgical
complications or negatively impact outcomes and should not be
used as a reason for avoiding RMB (Wood et al., 1999; Lechevallier
et al., 2000; Neuzillet et al., 2004).
CONCLUSION
The role of RMB in the setting of SRM has been expand-
ing, driven by the knowledge that approximately 20–50% of
SRM removed by surgical excision have benign (or relatively
indolent) pathology (Frank et al., 2003; Nguyen et al., 2006).
Additionally, low complications rates of RMB encourage its
wider adoption. Further, as RMB becomes a more routine
part of management of SRM, physicians will become increas-
ingly skilled at this procedure, likely decreasing failed biopsy
rates. Ongoing research continues to show promise in the
development of molecular, cytologic and histologic markers to
further characterize SRM and determine immunotherapy or
targeted systemic therapy suceptibility, predict tumor behav-
ior and outcomes, and discover new pathways in renal tumor
biology.
The selective utilization of RMB for diagnosis in renal masses
is a relatively uncommon approach when compared to manage-
ment of other neoplasms. In most other solid tumors, obtaining a
biopsy is one of the first steps in evaluating a patient and in mak-
ing an informed treatment decision. Clinicians can increasingly
risk-stratify patients based upon RMB results, leading to impor-
tant decisions such as whether to excise the tumor, likely safety of
AS, and potentially which type of systemic treatment regimen to
employ. With this ever-increasing data on the usefulness of RMB,
it may be time to increase utilization as part of routine practice in
the management of the SRM.
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